[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Antonios Likourezos\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":124},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,75,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100456772","single-dose-amikacin-for-uncomplicated-cystitis-in-the-ed-a-feasibility-study-100456772",false,"NCT05227937","Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study","Single Dose Amikacin for Uncomplicated Cystitis in the Emergency Department (ED): A Feasibility Study","Inclusion Criteria:\n\n* female emergency medicine patients\n* ≥14 years of age\n* uncomplicated urinary tract infection\n* a primary urinary complaint and nitrite-positive urine.\n\nExclusion Criteria:\n\n* pregnancy\n* abnormal genitourinary tract\n* recent urinary tract instrumentation\n* immunosuppression\n* CrCl \\\u003C 25 mL\u002Fmin\n* evidence of pyelonephritis or sepsis\n* any antibiotic treatment within 30 days\n* not available for phone follow-up in 3, 7, and 30 days\n* requires admission to the hospital\n* abnormal mental status.",true,"FEMALE","14 Years","110 Years",{"count":21,"type":22},75,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to determine if a single dose of amikacin (a type of antibiotic) can be used to effectively treat emergency department patients with uncomplicated cystitis (inflammation of the bladder). Participating in this study will allow the patient to treat their urinary tract infection (UTI) with a single intramuscular (IM (into the arm)) or intravenous (IV (into the vein)) shot of amikacin, rather than having to go to the pharmacy to pick up a prescription for antibiotics, and then take antibiotics for 3-7 days. A single dose of amikacin has been demonstrated to be safe, effective and well tolerated in other studies, but some patients may decline to participate because they do not wish to have an IV or IM shot, or because they don't want to speak on the phone with a research assistant three times over the next 30 days.",[26],"Urinary Tract Infections",[28,29,30],"urinary tract infections","amikacin","emergency medicine","RECRUITING","2026-03-02",{"date":34,"type":35},"2026-03-04","ACTUAL",{"date":37,"type":35},"2022-09-21",{"date":39,"type":22},"2026-12-31",{"name":41,"class":42},"Antonios Likourezos","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":43},"100568736","virtual-reality-and-standard-care-vs-standard-care-alone-for-acute-msk-pain-in-geriatric-ed-patients-100568736","NCT06685107","Virtual Reality and Standard Care vs. Standard Care Alone for Acute MSK Pain in Geriatric ED Patients","Combination of Virtual Reality and Standard of Care Versus Standard of Care Alone for Acute Musculoskeletal Pain Management in Geriatric Emergency Department Patients: A Randomized Clinical Trial","Inclusion Criteria:\n\n* age of 65+\n* Emergency Medicine patients\n* non traumatic musculoskeletal painful condition\n* pain score of 4+ on the numeric rating scale\n* patient will warrant parenteral analgesia per treating physician\n* patient will have to be awake, alert, and oriented to person, place, and time.\n* comprehension of informed consent process and study related content\n* ability to complete assessments\n\nExclusion Criteria:\n\n* painful syndrome requiring emergent and\u002For urgent pain control\n* altered mental status\n* unstable vital signs\n* history of recent epilepsy\n* seizure disorder\n* vertigo\n* active headache\n* nausea\n* motion sickness\n* dizziness","ALL","65 Years","120 Years",{"count":55,"type":22},180,"INTERVENTIONAL",[58],"NA","The proposed Virtual Reality as an Adjunct to Pain Management for Geriatric Patients in the ED (VRAP-ED) project will take place in the Emergency Medicine Department at Maimonides Medical Center. It seeks to enhance the analgesic practices for geriatric patients with acute painful conditions in the emergency setting. Although virtual reality (VR) has demonstrated effectiveness in reducing pain and anxiety in various clinical settings for juveniles and adults, the analgesic efficacy of VR for geriatric ED patients lacks established data. The project will use a geriatric-focused VR platform.\n\nThe project intends to improve pain management for almost 200 geriatric patients by evaluating the effectiveness of virtual reality (VR) in reducing pain and its impact on anxiety \\& stress reduction. The research project will conduct a randomized clinical trial to investigate the analgesic efficacy and impact on anxiety \\& stress by using VR as an adjunct to the standard of care (SOC) for pain management in elderly patients presenting to the ED with acute musculoskeletal pain. This will be investigated through a prospective, randomized, non-blinded clinical trial conducted over two years. Eligible patients will be randomly assigned to either the control (SOC) or intervention (SOC+VR) groups. The expected outcomes of this research study will provide insight into the feasibility of using VR in a busy emergency setting for one of the most commonly encountered painful syndromes and to assess the analgesic efficacy as well as the satisfaction of VR application by both patients and ED clinicians.",[61],"Acute Musculoskeletal Pain",[63,64,65,66],"Geriatric","Emergency Medicine","Virtual Reality","Acute Pain","2026-01-14",{"date":69,"type":35},"2026-01-16",{"date":71,"type":35},"2024-11-18",{"date":73,"type":22},"2027-12-31",{"name":41,"class":42},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":51,"minAge":82,"maxAge":52,"enrollmentInfo":83,"targetDuration":4,"studyType":56,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":98,"locationsCount":43},"100552477","phase-4-a-comparison-of-nurtec-odt-to-maxalt-mlt-odt-in-adult-ed-patients-with-migraine-headache-100552477","NCT06473597","A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache","A Comparison of Rimegepant Orally Disintegrating Tablet (Nurtec ODT) to Rizatriptan Benzoate Orally Disintegrating Tablet (Maxalt MLT-ODT) in Adult Patients Presenting to the ED With Migraine Headache: Randomized, Double-Blind, Clinical Trial","Inclusion Criteria:\n\n* Adult ED patients age 18 to 65 years old\n* Acute headache\n* Initial Pain score of 5 on a standard 11- point (score 0 to 10) numeric rating scale\n* Patients will have to be awake, alert, and oriented to person, place, and time\n* Patients able to demonstrate understanding of the informed consent process and content.\n* Patients also will have to demonstrate ability to verbalize the nature of any adverse effects they might experience as well as to express their pain severity by using the NRS.\n\nExclusion Criteria:\n\n* Allergy to Rimegepant or Rizatriptan\n* Pregnancy and breastfeeding\n* Unstable vital signs\n* Inability to provide consent\n* Suspicion for disease process other than migraine (those requiring emergent brain imaging, with a temperature of 100.4 °F, with objective neurologic findings, secondary headache (an \"organic\" headache))\n* Ischemic coronary artery disease (angina pectoris, history of myocardial infarction), coronary artery vasospasm (including Prinzmetal's angina)\n* History of stroke or transient ischemic attack\n* Peripheral vascular disease\n* Ischemic bowel disease,\n* Uncontrolled hypertension\n* Use of another 5-HT1 agonist, ergotamine-containing medications, or ergot-type medications (methylsergide)\n* Hemiplegic or basilar migraine\n* Concurrent administration or recent discontinuation (within 2 weeks) of a MAO-A inhibitors\n* Current use of Rimegepant as a prophylactic\n* Severe Nausea and Vomiting\n* Severe headache requiring immediate intervention\n* Severe hepatic impairment\n* If taking any of the following medications (contraindications):\n\n  * Monoaminoxidaze (MAO) inhibitors (isocarboxazid, linezolid, metaxalone, methylene blue, moclobemide, phenelzine, procarbazine, rasagiline, safinamide, selegiline, tranylcypromine)\n  * SSRI- Citalopram, Escitalopram, Sertraline\n  * Triptans: Sumatriptan, Zolmitriptan, Imigran\n  * Almotriptan.\n  * Cabergoline.\n  * Dihydroergotamine.\n  * Dihydroergotamine intranasal\n  * Eletriptan\n  * Ergoloid mesylates\n  * Ergotamine\n  * Frovatriptan\n  * Duloxetine\n  * Cyclobenzaprine\n  * Fluoxetine, velafaxine\n  * Trazodone\n  * Tramadol\n  * TCA: nortriptyline (Pamelor), amitriptyline, protriptyline\n  * Amphetamines: methamphetamine (Desoxyn), dextroamphetamine (Adderall, Adderall XR), dextroamphetamine (Dexedrine)\n  * azole antifungals ( ketoconazole, itraconazole)\n  * macrolide antibiotics (clarithromycin, erythromycin)\n  * rifamycins (such as rifampin, rifabutin)\n  * carbamazepine, phenytoin\n  * Cardiac Drug: amiodarone (Nexterone, Pacerone), quinidine, ranolazine (Aspruzyo Sprinkle), verapamil (Verelan, Verelan PM)","18 Years",{"count":84,"type":22},80,[86],"PHASE4","Rimegepant (Nurtec) is an orally administered small molecule CGRP receptor antagonist with efficacy in the acute treatment of migraine. Rizatriptan benzoate (MAXALT), is a selective 5-hydroxytryptamine1B\u002F1D (5-HT1B\u002F1D) receptor agonist. Rizatriptan binds with high affinity to human cloned 5-HT1B and 5-HT1D receptors which leads to activation of these receptors results in cranial vessel constriction, inhibition of neuropeptide release and reduced transmission in trigeminal pain pathways with resultant relieve of the headache.\n\nTeh investigators hypothesize that the administration of Rimegepant ODT would provide better analgesic efficacy than Rizatriptan ODT with respect to analgesic efficacy at 60 min and 120 minutes in ED patients with acute headache.\n\nThis is a prospective, randomized, double-blind superiority trial evaluating and comparing analgesic efficacy and safety of Rimegepant ODT 75 mg to Rizatriptan ODT 10 mg in adult patients presenting to the Emergency Department of Maimonides Medical Center with acute migraine headache.",[89],"Migraine",[89,91,64],"Headache","2025-09-30",{"date":94,"type":35},"2025-10-01",{"date":96,"type":35},"2024-09-01",{"date":39,"type":22},{"name":41,"class":42},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":51,"minAge":82,"maxAge":53,"enrollmentInfo":107,"targetDuration":4,"studyType":56,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":123,"locationsCount":43},"100544104","phase-4-nebulized-ketamine-to-nebulized-fentanyl-for-treating-acute-painful-conditions-in-the-ed-100544104","NCT06364540","Nebulized Ketamine to Nebulized Fentanyl for Treating Acute Painful Conditions in the ED","Comparison of Nebulized Ketamine to Nebulized Fentanyl for Treating Acute Painful Conditions in the ED: A Prospective, Randomized, Double-Blind Clinical Trial.","KETAFEN","Inclusion Criteria:\n\n* age 18+ years\n* acute painful condition\n* pain score of 5 or more on a standard 11 point numeric rating scale (NRD)\n* patient needs to be awake, alert, and oriented as to person, place, and time\n* demonstrated understanding of the informed consent process and content\n* patient needs to demonstrate the ability to verbalize the nature of any adverse effects (AE)\n* patient needs to experience as well as express their pain severity by using the NRS\n\nExclusion Criteria:\n\n* patient with a painful condition warranting emergent\u002Furgent intervention in the ED\n* patients with altered mental status\n* allergy to ketamine or fentanyl\n* pregnant or breastfeeding\n* weight greater than 100 kg\n* patients presenting with head injury\n* unstable vital signs (systolic blood pressure \\\u003C90 mmHg or \\>180 mmHg, pulse rate \\\u003C50 beats\u002Fmin or \\>150 beats\u002Fmin, and respiration rate \\\u003C10 breaths\u002Fmin or \\>30 breaths\u002Fmin)\n* inability to provide consent\n* current medical history of alcohol or drug abuse\n* administration of opioids or opioid antagonist\u002Fagonist within 4-6 hours prior to arrival and NSAIDs 6 hours prior to arrival to the t",{"count":108,"type":22},150,[86],"In situations where intravenous access is not readily available or is unobtainable and the intranasal route is not feasible, another non-invasive route of ketamine administration, such as inhalation via breath-actuated Nebulizer (BAN), is becoming a viable alternative. The BAN allows the controlled, patient-initiated delivery of analgesics in a measured and titratable fashion. (18) Ketamine has been studied as a nebulized drug in a lot of different settings and for a lot of different reasons, such as to treat acute pain after surgery (like a sore throat after being intubated), as a pre-medication for general anesthesia, to treat cancer pain, and as a therapy for asthmaticus.\n\nOur research team has published two case series of 10 adult patients who were given nebulized ketamine (via BAN) for a variety of acute traumatic and non-traumatic painful conditions. The patients showed a 60% decrease in pain and a small number of side effects. Furthermore, our group published a randomized, double-blind trial of 120 adult patients evaluating the analgesic efficacy and safety of nebulized ketamine at three different dosing regimens for acute pain in the ED (0.75 mg\u002Fkg, 1 mg\u002Fkg, and 1.5 mg\u002Fkg), showing similar analgesic efficacy between the three different dosing regimens for short-term (up to 120 minutes) pain relief. Lastly, we recently completed a randomized, double-blind, double-dummy clinical trial comparing the analgesic efficacy and safety of nebulized ketamine and intravenous ketamine in managing acute pain in adult ED patients, with data currently being analyzed.\n\nNebulized fentanyl given in the ED to adults with acute traumatic and non-traumatic pain syndromes at a dose range of 1.5-4 mcg\u002Fkg showed the same or even better pain-relieving effects than IV fentanyl and IV morphine alone.\n\nOur objective is to compare the analgesic efficacy and rates of side effects of a 0.75 mg\u002Fkg dose of ketamine administered via breath-actuated nebulizer (BAN) to a dose of 3 mcg\u002Fkg of fentanyl administered via breath-actuated nebulizer (BAN) in adult patients presenting to the ED with acute painful conditions.",[112],"Pain, Acute",[114,115,30,116],"pain","acute","clinical tiral","2025-05-30",{"date":119,"type":35},"2025-06-04",{"date":121,"type":35},"2024-05-01",{"date":39,"type":22},{"name":41,"class":42},""]